Header

UZH-Logo

Maintenance Infos

The power of the EUSTAR cohort: key findings to date and implicationsfor management of systemic sclerosis patients


Benvenuti, Francesco; Zanatta, Elisabetta; Avouac, Jérôme; Müller-Ladner, Ulf; Cozzi, Franco; Hoffmann-Vold, Anna-Maria; Gabrielli, Armando; Distler, Oliver; Matucci-Cerinic, Marco; Allanore, Yannick; Doria, Andrea (2020). The power of the EUSTAR cohort: key findings to date and implicationsfor management of systemic sclerosis patients. Expert Review of Clinical Immunology, 16(11):1065-1074.

Abstract

INTRODUCTION The rarity of systemic sclerosis (SSc) and its widely heterogeneous presentation and disease course are the main limitations for clinical research. The European Scleroderma Trials and Research group (EUSTAR) was launched in 2004, aiming to unify research efforts in the field of SSc. The central EUSTAR database has grown exponentially over the years, promoting new research and clinical trials, shedding new light on SSc diagnosis, its clinical course and providing new ideas for state-of-the-art therapy.Areas covered: The authors summarized key findings of the main EUSTAR studies by reviewing PubMed and Web-of-Science databases through July 2020. The authors focused on the very early diagnosis of SSc, the prediction of disease course and mortality, the evaluation of disease activity and quality of life, the general management and therapy.Expert opinion: The findings elucidated in EUSTAR studies have substantially improved the diagnostic and therapeutic approach to SSc in the last fifteen years. Further efforts are warranted to identify early prognostic markers of the disease and stratify patients who may benefit most from vasoactive, immunosuppressive, and/or antifibrotic therapy. This will be particularly important in leading the future of SSc towards precision medicine and to promote more targeted clinical trials.

Abstract

INTRODUCTION The rarity of systemic sclerosis (SSc) and its widely heterogeneous presentation and disease course are the main limitations for clinical research. The European Scleroderma Trials and Research group (EUSTAR) was launched in 2004, aiming to unify research efforts in the field of SSc. The central EUSTAR database has grown exponentially over the years, promoting new research and clinical trials, shedding new light on SSc diagnosis, its clinical course and providing new ideas for state-of-the-art therapy.Areas covered: The authors summarized key findings of the main EUSTAR studies by reviewing PubMed and Web-of-Science databases through July 2020. The authors focused on the very early diagnosis of SSc, the prediction of disease course and mortality, the evaluation of disease activity and quality of life, the general management and therapy.Expert opinion: The findings elucidated in EUSTAR studies have substantially improved the diagnostic and therapeutic approach to SSc in the last fifteen years. Further efforts are warranted to identify early prognostic markers of the disease and stratify patients who may benefit most from vasoactive, immunosuppressive, and/or antifibrotic therapy. This will be particularly important in leading the future of SSc towards precision medicine and to promote more targeted clinical trials.

Statistics

Citations

Altmetrics

Additional indexing

Item Type:Journal Article, refereed, further contribution
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Rheumatology Clinic and Institute of Physical Medicine
Dewey Decimal Classification:610 Medicine & health
Language:English
Date:November 2020
Deposited On:27 Oct 2020 16:48
Last Modified:09 Jan 2021 02:05
Publisher:Taylor & Francis
ISSN:1744-666X
OA Status:Closed
Publisher DOI:https://doi.org/10.1080/1744666X.2021.1836962
PubMed ID:33076716

Download

Full text not available from this repository.
View at publisher

Get full-text in a library